AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64%

ARX Aroa Biosurgery Limited

Healthcare · Medical Devices · website
$0.56
52wk 0.49 – 0.80
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Aroa Biosurgery Limited

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$192.45M
P/E (trailing)
55.50
P/E (forward)
18.79
EPS (trailing)
0.01
Dividend yield
Payout ratio
0.0%
Beta
0.85
EV / EBITDA
19.93
Price / Book
2.31
ROE
4.9%
Operating margin
12.0%
Net margin
4.5%
Total cash
$27.14M
Total debt
$6.38M
Current ratio
4.77
Debt / Equity
0.06
Free cash flow
$6.57M
Avg volume
239,582
Latest annual results (FY ending 31 Mar 2026)
  • Revenue$86.60M
  • Gross profit$74.07M
  • Operating income-$519.51K
  • Net income$3.90M
  • Diluted EPS0.01
  • Free cash flow$5.68M
  • Net debt-$12.25M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9